Salivary anti-cyclic citrullinated peptide as a screening tool for rheumatoid arthritis

This study aims to evaluate the sensitivity and specificity of salivary anti-cyclic citrullinated peptide 3 (anti-CCP3) for the early diagnosis of rheumatoid arthritis. Between June 2017 and April 2019, a total of 63 patients with rheumatoid arthritis (10 males, 53 females; mean age: 50.4±9.5 years;...

Full description

Saved in:
Bibliographic Details
Published inArchives of rheumatology Vol. 38; no. 1; pp. 95 - 100
Main Authors Mortazavi, Nazanin, Abdolahi, Nafiseh, Saeidi, Mohsen, Ali Vakili, Mohammad, Mohebrad, Pouria
Format Journal Article
LanguageEnglish
Published Turkey Turkish League Against Rheumatism 01.03.2023
Prof Sebnem Ataman, President Turkish League Against Rheumatism
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This study aims to evaluate the sensitivity and specificity of salivary anti-cyclic citrullinated peptide 3 (anti-CCP3) for the early diagnosis of rheumatoid arthritis. Between June 2017 and April 2019, a total of 63 patients with rheumatoid arthritis (10 males, 53 females; mean age: 50.4±9.5 years; range, 27 to 74 years) and 49 healthy controls (8 males, 41 females; mean age: 49.3±9.3 years; range 27 to 67 years) were included. Salivary samples were collected by passive drooling. Anti-cyclic citrullinated peptide analyses of salivary and serum samples were performed. The mean polyclonal immunoglobulin (Ig)G-IgA anti-CCP3 salivary levels were significantly different in patients (149.2±134.2) compared to healthy controls (28.5±23.9). The mean polyclonal IgG-IgA anti-CCP3 serum levels were measured as 254.0±169.5 in patients and 3.8±3.6 in healthy individuals. The diagnostic accuracy analysis of salivary IgG-IgA anti-CCP3 results in an area under the curve (AUC) of 0.818, as well as 91.84% specificity and 61.90% sensitivity. Salivary anti-CCP3 may be considered as an additional screening test for rheumatoid arthritis.
ISSN:2148-5046
1309-0291
2618-6500
1309-0283
DOI:10.46497/ArchRheumatol.2023.9032